ㆍDAILY PROGRAMㆍPROGRAM AT A GLANCE

DAILY PROGRAM

  • 08:50-09:00

  • Opening Remarks

    Pierce Chow (National Cancer Centre Singapore, Singapore)

09:00-10:35

Session 1. Changes in the Landscape of HCC

Chairs: Kwang-Hyub Han (CHA Univ., Seoul), Kengo Yoshimitsu (Fukuoka Univ., Fukuoka)

  • 09:00-09:20

  • Changing Etiology and Epidemiology of HCC: Asia and Worldwide

    Do Young Kim (Yonsei Univ., Seoul)

  • 09:20-09:40

  • New Concepts in the Imaging Diagnosis of HCC: Can Artificial Intelligence Help?

    Chih-Horng Wu (National Taiwan Univ., Taipei)

  • 09:40-10:00

  • Molecular Heterogeneity in HCC and the Challenge of Identifying Predictive Biomarkers

    Irene Oi-Lin Ng (The Univ. of Hong Kong, Hong Kong)

  • 10:00-10:20

  • Adaptation of Practice Guidelines: When East Meets West

    Li-Tzong Chen (Kaohsiung Medical Univ., Kaohsiung)

  • 10:20-10:35

  • Q&A

  • 10:35-10:50

  • Coffee Break

10:50-12:25

Session 2. Translational and Basic Research That May Impact on the Clinical Management of HCC

Chairs: Pierce Chow (National Cancer Centre Singapore, Singapore), Chiun Hsu (National Taiwan Univ., Taipei)

  • 10:50-11:10

  • Biomarker-Based Precision Pharmacotherapy in HCC

    Takahiro Kodama (Osaka Univ., Osaka)

  • 11:10-11:30

  • Translational Research: The Impact from Research in Epigenomics

    Ah-Jung Jeon (Mirxes, Singapore)

  • 11:30-11:50

  • Translational Research: The Impact from Research in Spatial Transcriptomics

    Ankur Sharma (Harry Perkins Institute of Medical Research, Perth)

  • 11:50-12:10

  • The Promise of Immuno-Neoadjuvant Therapy in HCC

    Han Chong Toh (National Cancer Centre Singapore, Singapore)

  • 12:10-12:25

  • Q&A

  • 12:25-13:30

  • Luncheon Symposium & Networking [Eisai] Invitation ->

13:30-15:05

Session 3. Unmet Clinical Need in and Current Clinical Research Directions

Chairs: Etsuro Hatano (Kyoto Univ., Kyoto), Thomas Yau (The Univ. of Hong Kong, Hong Kong)

  • 13:30-13:50

  • Early HCC and Treatment with Curative Intent - Has Adjuvant Therapy Opened a New Paradigm?

    Linda Wong (Univ. of Hawaii, Honululu)

  • 13:50-14:10

  • Intermediate-Stage HCC: Re-Defining the Role of Liver-Directed Therapy

    Hyo-Cheol Kim (Seoul National Univ., Seoul)

  • 14:10-14:30

  • Intermediate-Stage HCC: Expanding the Role of Systemic Therapy

    Masafumi Ikeda (National Cancer Center Hospital East, Kashiwa)

  • 14:30- 14:50

  • Advanced HCC: Beyond IMbrave 150 and HIMALAYA

    Chih-Hung Hsu (National Taiwan Univ., Taipei)

  • 14:50-15:05

  • Q&A

  • 15:05-15:20

  • Coffee Break

15:20-16:40

Session 4. From APPLE Academy into the Future

Chairs: Masatoshi Kudo (Kindai Univ., Osaka), Jian Zhou (Fudan Univ., Shanghai)

  • 15:20-15:45

  • Investigator-Initiated Trials for HCC in the Asia-Pacific Region

    Pierce Chow (National Cancer Centre Singapore, Singapore)

  • 15:45-16:05

  • APPLE Association as a Platform for Future International Research Collaboration

    Kwang-Hyub Han (CHA Univ., Seoul)

  • 16:05-16:25

  • Promoting the Next-Generation Liver Cancer Experts to the Global Arena

    Ann-Lii Cheng (National Taiwan Univ., Taipei)

  • 16:25-16:40

  • Q&A

  • 16:40-16:45

  • Closing Remark

    Norihiro Kokudo (National Center for Global Health and Medicine, Tokyo)